RSL3 is the inhibitor of the glutathione (GSH) peroxidase 4, which can inhibit the cysteine/glutamate amino acid transporter system. RSL3 blocks GSH synthesis with an IC50 of 100 nM. RSL3, that are synthetically lethal with cell lines expressing mutant HRAS and KRAS1.
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
|Solubility||DMSO: ≥ 30 mg/mL|
Nrf2 inhibition reverses resistance to GPX4 inhibitor-induced ferroptosis in head and neck cancer
Daiha Shin, et al. Free Radic Biol Med. 2018 Dec;129:454-462. PMID: 30339884.
RSL3 and Erastin differentially regulate redox signaling to promote Smac mimetic-induced cell death.
Dachert J, et al. Oncotarget. 2016 Sep 27;7(39):63779-63792. PMID: 27588473.
Oncogenic RAS Mutants Confer Resistance of RMS13 Rhabdomyosarcoma Cells to Oxidative Stress-Induced Ferroptotic Cell Death.
Schott C, et al. Front Oncol. 2015 Jun 22;5:131. PMID: 26157704.
Development of small-molecule probes that selectively kill cells induced to express mutant RAS.
Weiwer M, et al. Bioorg Med Chem Lett. 2012 Feb 15;22(4):1822-6. PMID: 22297109.
|Related Ferroptosis Products|
|Imidazole ketone erastin
Imidazole ketone erastin (IKE) is an inducer of ferroptosis, and it is also a potent, selective, and metabolically stable inhibitor of the cystine-glutamate antiporter, system Xc-.
UAMC-3203 hydrochloride is a potent and selective Ferroptosis inhibitor, with an IC50 of 12 nM.
Liproxstatin-1 is a potent inhibitor of ferroptosis, a non-apoptotic form of cell death characterized by iron-dependent accumulation of lethal lipid reactive oxygen species (ROS).
CIL56 (CA3) is a potent and selective ferroptosis inducer, it has potent inhibitory effects on YAP1/Tead transcriptional activity and primarily targets YAP1 high and therapy-resistant esophageal adenocarcinoma cells endowed with CSC properties.
Deferoxamine mesylate as a chelating agent used to remove excess iron from the body.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.